echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Heavy-duty innovative drugs closely "approved", a number of innovative enterprises pile up "listing"

    Heavy-duty innovative drugs closely "approved", a number of innovative enterprises pile up "listing"

    • Last Update: 2020-07-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: Last week: Three PD-1s were approved, and six major companies went publicis obvious to all, in recent years, biopharmaceuticals have become one of the fastest growing sub-sectors in the pharmaceutical industry, of which monoto-resistance is the largest category of biological drugsWith the domestic innovation into the harvest period, the results continue to appear in turn, only last week there were three PD-1 innovative drugs were approved for the market, and before the comparison, the rate of harvest of innovative drugs is gradually acceleratingthe "NBA All-Star Competition" of innovative biological drugs""Sansheng Pharmaceuticals" anti-HER2 monoantinia monotolita is approved for sale for the treatment of HER2 overexpression of metastatic breast cancer;(Henri Pharmaceuticals) Injection with Carelli Zuma Xvaccine approved to increase the number of 3, 4 indications: the former is a combination of permeitus and karpan for epidermal growth factor receptor (EGFR) gene mutation negative and interstitial lymphoma kinase (ALK) First-line treatment of partially advanced or metastatic non-small cell lung cancer (NSCLC) that is negative and non-surgically removed;this may be with the continuous improvement of domestic demand and ability to pay, health insurance coverage and the continued expansion of listed varieties, China's single resistance market gradually ushered in a period of rapid developmentAt present, the domestic single resistance research and development of the hot scene is the best proof, many participants, the market prospects can be expectedPicture Source: Shanxi Securities Researchand last week, from the pharmaceutical manufacturing capital market performance, biological products and pharmaceutical biology as a whole in the industry front, is expected to be in a short period of time, the situation will continue to developat the same time, the domestic single-resistance intensive listing road, but also announced that the innovative pharmaceutical industry will enter a competitive stage, research and development technology strength, research and development pipeline, gradient, research and development progress, production scale and cost control will become the key factors of the front-end enterprises to open the gap, such as the NBA All-Star game version of the hot battlefield gradually beganinnovative biologics" "NBA rookie competition""Gan Li Pharmaceuticals" June 16 online purchase, will be listed on the main boardThe IPO issued 40.2 million new shares, raising a total of 2.545 billion yuan, and the,Fudan Zhangjiang, listed on June 19The IPO issued 120 million new shares, raising a total of 1.074 billion yuan, and .S IPO issued 15 million new shares, raising a total of 1.056 billion yuan; at the same time, on the other hand, domestic biopharmaceutical enterprises are also in the pile of listing, according to relevant media reports, last week two tumor genetic testing enterprises "Panshengs" and "stone-burning medicine" landed in the United States shares; To some extent, it also represents the "new show" of the innovative and biopharmaceutical industry perhaps due to policy support and pharmaceutical enterprises to increase investment in research and development, not only domestic innovative drugs have landed to attract attention, pharmaceutical and biological investment in the field of heat is also the capital market concern Regardless of domestic and foreign, the frequency of listing and financing of pharmaceutical enterprises significantly accelerated, especially under the influence of the epidemic in the field of biomedicine is further highlighted, coupled with domestic science and technology board listing reform and other policy changes, domestic research and development investment has gradually entered the harvest period, and the industry is expected to continue to maintain a high degree of business climate at the same time, to maintain the strength of the follow-up equally exciting summary in short, with the transition of time, the development of the industry, innovative biopharmaceutical stakes will be more intense by the capital market, such as HengRui and other enterprises such as strong research and development of leading enterprises to favor the capital is no longer need to say, on the contrary, research and development strength is not strong small and medium-sized enterprises on the CRO industry dependence may be further , unwittingly, it seems that the war in the field of innovative drugs has gradually shifted between leading pharmaceutical companies and CRO companies But the strength and weakness, the victory or the loss, still do not know, only to wait and see .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.